1). Mathe G., Schwarzenberg L. Bone marrow transplantation (1958-1978): conditioning and graft-versus-host disease, indications in aplasias and leukemias. Pathol Biol (Paris). 1979. 27:337–43.
2). Storb R., Santos GW. Application of bone marrow transplantation in leukaemia and aplastic anaemia. Clin Haematol. 1983. 12:721–37.
Article
3). Horowitz MM., Gale RP., Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990. 75:555–62.
Article
4). Weiden PL., Sullivan KM., Flournoy N., Storb R., Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981. 304:1529–33.
5). Transplant or chemotherapy in acute myelogenous leukaemia. International Bone Marrow Transplant Registry. Lancet. 1989. 1:1119–22.
6). Kumar L. Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol. 1994. 12:1710–7.
Article
7). Mrsic M., Horowitz MM., Atkinson K, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone marrow transplant. 1992. 9:269–75.
8). Mortimer J., Blinder MA., Schulman S, et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol. 1989. 7:50–7.
Article
9). Kolb HJ., Mittermuller J., Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990. 76:2462–5.
Article
10). Kolb HJ., Schattenberg A., Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995. 86:2041–50.
11). Collins RH Jr., Shpilberg O., Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997. 15:433–44.
Article
12). Zeiser R., Bertz H., Spyridonidis A., Houet L., Finke J. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant. 2004. 34:923–8.
Article
13). Dey BR., McAfee S., Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003. 9:320–9.
Article
14). Bethge WA., Hegenbart U., Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood. 2004. 103:790–5.
Article
15). Lee S., Park S., Kim BK, et al. Donor leukocyte infusion as treatment for relapsed leukemia after allogeneic bone marrow transplantation: graft- versus-leukemia effect. Korean J Hematol. 1999. 34:252–62.
16). Glucksberg H., Storb R., Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974. 18:295–304.
Article
17). Maris MB., Niederwieser D., Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003. 102:2021–30.
Article
18). McSweeney PA., Niederwieser D., Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001. 97:3390–400.
Article
19). Niederwieser D., Maris M., Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003. 101:1620–9.
Article
20). Kolb HJ., Schattenberg A., Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995. 86:2041–50.
21). Weisser M., Tischer J., Schnittger S., Schoch C., Ledderose G., Kolb HJ. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica. 2006. 91:663–6.
22). Savani BN., Montero A., Kurlander R., Childs R., Hensel N., Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005. 36:1009–15.
Article
23). Keil F., Haas OA., Fritsch G, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood. 1997. 89:3113–7.
Article
24). Mackinnon S., Papadopoulos EB., Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995. 86:1261–8.
Article
25). Shiobara S., Nakao S., Ueda M, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant. 2000. 26:769–74.
Article